Drug Trial Radar · NCT07219459
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
104
Planned (sponsor's estimate)
Start
Mar 19, 2026
Primary completion
Sep 2029
Study completion Sep 2031
Sponsor
- Lead sponsor
- CatalYm GmbHIndustry
- Sponsor type
- Industry
- First posted
- Oct 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2b, randomized, blinded clinical trial investigating the efficacy and safety of visugromab in combination with nivolumab and Lenvatinib compared to double placebo and Lenvatinib in participants with unresectable or metastatic HCC and compensated liver function (Child-Pugh A) after failure of 1L treatment that included an anti-PD-(L)1 compound. The trial consists of 2 Parts: a non-randomized Safety-run-in part (Part 1) and the subsequent randomized part (Part 2) with 2 treatment arms (A and B). Randomization of participants into Treatment Arm A and B will continue until 40 efficacy-evaluable participants are enrolled into each Treatment Arm.
Conditions
- Unresectable or Metastatic Hepatocellular Carcinoma
- Child-Pugh A Hepatocellular Carcinoma
- Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
Interventions
Visugromab RDE (recommended dose for expansion)Biological
Participants receive visugromab (RDE) intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments
NivolumabBiological
Participants receive Nivolumab 360mg intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments after visugromab infusion
LenvatinibDrug
Participants receive Lenvatinib per os (PO) once daily according to body weight (\> 60kg: 12mg; \< 60kg: 8mg)
Placebo Saline InfusionOther
Saline (0.9%NaCl) intravenous (2x IV) on Day 1 of every 21-day cycle every 3 weeks (Q3W) for up to 35 treatments
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: up to 36 months
Locations
29 sites in 7 countries. Site status is shown where the registry gives one.
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
USC Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
UC Irvine Health. Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
UCLA Hematology/Oncology - Santa Monica
Santa Monica, California · Recruiting
Peidmont Healthcare, Inc
Atlanta, Georgia · Recruiting
OSF St. Francis Medical Center
Peoria, Illinois · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Montpellier University Hospital Center - Saint Eloi Hospital
Montpellier, France · Recruiting
Centre Hospitalier Universitaire de Bordeaux - Hôpital Haut-Lévêque
Pessac, France · Recruiting
Poitiers University Hospital Center - Miletrie Hospital
Poitiers, France · Recruiting
Gustave Roussy
Villejuif, France · Recruiting
Universitätsklinikum Frankfurt Johann Wolfgang Goethe- Universität
Frankfurt, Germany · Recruiting
Hannover Medical School
Hanover, Lower Saxony, Germany · Recruiting
University Hospital Cologne, Clinic of Gastroenterology and Hepatology
Cologne, North Rhine-Westphalia, Germany · Recruiting
University Medical Center of Johannes Gutenberg University Mainz
Mainz, Rhineland-Palatinate, Germany · Recruiting
Polyclinic S. Orsola-Malpighi
Bologna, Italy · Recruiting
Ospedale San Raffale, IRCCS
Milan, Italy · Recruiting
Asst Grande Ospedale Metropolitano Niguarda
Milan, Italy · Recruiting
Ospedale S.Maria delle Croci
Ravenna, Italy · Recruiting
University Hospital Miguel Servet
Zaragoza, Aragon, Spain · Recruiting
Catalan Institute of Oncology, Hospital Duran i Reynals
L'Hospitalet de Llobregat, Barcelona, Spain · Recruiting
Hospital Clinic of Barcelona
Barcelona, Catalonia, Spain · Recruiting
University Clinic of Navarra - Pamplona
Pamplona, Chartered Community of Navarra, Spain · Recruiting
University Hospital Ramon y Cajal
Madrid, Madrid, Spain · Recruiting
Chia-Yi Christian Hospital
Chiayi City, Taiwan · Recruiting
Taipei Veterans General Hospital
Taipei, Taiwan · Recruiting
Western General Hospital
Edinburgh, United Kingdom · Recruiting
King's College Hospital
London, United Kingdom · Recruiting
The Christie NHS Foundation Trust
Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.